Ratan Capital Management LP Boosts Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Ratan Capital Management LP increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 522.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 179,307 shares of the company’s stock after acquiring an additional 150,507 shares during the quarter. Janux Therapeutics makes up about 1.5% of Ratan Capital Management LP’s portfolio, making the stock its 17th biggest holding. Ratan Capital Management LP’s holdings in Janux Therapeutics were worth $9,600,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Franklin Resources Inc. boosted its stake in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after buying an additional 7,442 shares during the period. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the fourth quarter valued at about $139,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock valued at $596,000 after acquiring an additional 1,095 shares during the period. Finally, Chicago Capital LLC acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $230,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Wedbush reissued an “outperform” rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank cut their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Stock Down 10.7%

Shares of JANX opened at $22.62 on Thursday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -19.33 and a beta of 3.24. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71. The stock has a 50 day moving average price of $28.89 and a 200 day moving average price of $41.16.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,333 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total transaction of $106,755.99. Following the completion of the sale, the insider now directly owns 82,139 shares of the company’s stock, valued at $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction on Friday, March 7th. The stock was bought at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the purchase, the director now directly owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 10,001 shares of company stock worth $313,964. Corporate insiders own 8.10% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.